Fidelity International’s Revance Therapeutics, Inc. RVNC Stock Holding History

Fidelity International’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,196,095	Closed	-$12.8M	–	989
2024 Q4	$12.8M	Buy	4,196,095 +3,162	+0.1%	+$13.8K	0.01%	513
2024 Q3	$21.8M	Buy	+4,192,933	New	+$20.8M	0.02%	449
2015 Q4	–	Sell	-44,064	Closed	-$1.31M	–	528
2015 Q3	$1.31M	Hold	44,064	–	–	﹤0.01%	466
2015 Q2	$1.41M	Buy	+44,064	New	+$1.13M	﹤0.01%	496

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Fidelity International's RVNC Position: Q1 2025 in Review

Fidelity International sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 4,196,095 shares — an estimated $12.8M sold.

Fidelity International first reported a position in RVNC in Q2 2015 and held it in 4 quarters. The position peaked at $21.8M in Q3 2024. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Fidelity International reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Fidelity International sold 4,196,095 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $12.8M.
Fidelity International first reported a position in Revance Therapeutics, Inc. in Q2 2015 and held it in 4 quarters.
Fidelity International's Revance Therapeutics, Inc. position peaked at $21.8M in Q3 2024.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Fidelity International's 13F filing for Q1 2025, filed 12 May 2025.